The Radiology Assistant : RECIST 1.1 - and more
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
Présentation PowerPoint
Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment - Ying-Chieh Lai, Wen-Cheng Chang, Chun-Bing Chen, Chi-Liang Wang, Yu-Fen Lin, Ming-Mo Ho,
How to better understand iRECIST – a new wave in immunotherapeutic
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria | RadioGraphics
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patient
Assessing Immunotherapy Response and Progression
ABSTRACT INTRODUCTION BACKGROUND AND HISTORY
Novel oncologic therapy response criteria (iRECIST and more) - Mint Medical GmbH
CDISC Compliant Implementation of iRECIST and LYRIC for Immunomodulatory Therapy Trials
The Radiology Assistant : RECIST 1.1 - and more
The Radiology Assistant : RECIST 1.1 - and more
PDF) Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
Statistical Analysis Plan Title: A Phase 1/2, Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combin
Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis | Journal for ImmunoTherapy of Cancer
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics - The Lancet Oncology
iRECIST: how to do it | Cancer Imaging | Full Text
